TMO

$698.342.30%15.69

After Hours: 700.00+1.66 +0.24%

Thermo Fisher Scientific Inc (TMO)

Date: O: H: L: C: Vol:

Thermo Fisher Scientific Inc stock is traded at $698.34, with a volume of 1,623,708. It is up +2.30% in the last 24 hours and up +6.65% over the past month. Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2025 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).

Previous Close:

$682.65

Open:

$677.92

24h Volume:

1,623,708

Relative Volume:

0.73

Market Cap:

$258.75B

Revenue:

$45.20B

Net Income/Loss:

$6.87B

P/E Ratio:

38.39

EPS:

$18.19

Net Cash Flow:

$6.75B

1W Performance:

+0.77%

1M Performance:

+6.65%

6M Performance:

+48.83%

1Y Performance:

+23.63%

1-Day Range:

$671.99$700.20

1-Week Range:

$671.99$711.85

52-Week Range:

$435.27$711.85

Thermo Fisher Scientific Inc Stock (TMO) Company Profile

Name

Thermo Fisher Scientific Inc

Sector

Healthcare

Industry

Diagnostics & Research

Phone

(781) 622-1000

Address

168 THIRD AVENUE, WALTHAM, MA, USA

Employee

125,000

@thermofisher

Next Earnings Date

null

Latest SEC Filings

SEC

TMO's Discussions on X

Market Cap

Revenue

Net Income

Cash Flow

EPS

Thermo Fisher Scientific Inc Stock (TMO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-09-26	Upgrade	UBS	Neutral → Buy
Sep-03-26	Initiated	CLSA	Outperform
Jun-26-26	Resumed	Bernstein	Mkt Perform
Jun-11-26	Initiated	Piper Sandler	Neutral
Jun-03-26	Downgrade	HSBC Securities	Buy → Hold
Jun-02-26	Resumed	Wolfe Research	Outperform
May-15-26	Resumed	RBC Capital Mkts	Sector Perform
Mar-27-26	Initiated	DZ Bank	Buy
Dec-11-25	Upgrade	Citigroup	Neutral → Buy
Dec-09-25	Initiated	Goldman	Buy
Dec-08-25	Upgrade	KeyBanc Capital Markets	Sector Weight → Overweight
Dec-02-25	Resumed	Morgan Stanley	Overweight
Dec-01-25	Upgrade	HSBC Securities	Hold → Buy
Sep-11-25	Upgrade	Barclays	Equal Weight → Overweight
Aug-19-25	Initiated	William Blair	Outperform
Jul-24-25	Downgrade	HSBC Securities	Buy → Hold
Jul-11-25	Upgrade	Scotiabank	Sector Perform → Sector Outperform
Jul-09-25	Downgrade	UBS	Buy → Neutral
Jan-10-25	Upgrade	Bernstein	Mkt Perform → Outperform
Dec-23-24	Initiated	Scotiabank	Sector Perform
Oct-14-24	Initiated	Redburn Atlantic	Buy
Oct-01-24	Initiated	Stephens	Overweight
Aug-28-24	Initiated	Wells Fargo	Overweight
Jun-03-24	Resumed	Jefferies	Buy
Mar-18-24	Resumed	Citigroup	Neutral
Jan-24-24	Downgrade	Barclays	Overweight → Equal Weight
Jan-08-24	Downgrade	Bernstein	Outperform → Mkt Perform
Dec-18-23	Initiated	HSBC Securities	Buy
Dec-13-23	Initiated	Wolfe Research	Outperform
Oct-26-23	Downgrade	KeyBanc Capital Markets	Overweight → Sector Weight
Oct-25-23	Upgrade	Wells Fargo	Underweight → Equal Weight
Sep-28-23	Initiated	Bernstein	Outperform
Sep-06-23	Resumed	Citigroup	Buy
Jul-19-23	Initiated	Raymond James	Outperform
Jul-19-23	Reiterated	Robert W. Baird	Outperform
Jul-13-23	Upgrade	Credit Suisse	Neutral → Outperform
Apr-04-23	Reiterated	Barclays	Overweight
Dec-14-22	Initiated	Deutsche Bank	Buy
Dec-07-22	Initiated	RBC Capital Mkts	Outperform
Oct-27-22	Downgrade	The Benchmark Company	Buy → Hold
Aug-25-22	Initiated	Credit Suisse	Neutral
Apr-25-22	Downgrade	Wells Fargo	Equal Weight → Underweight
Jan-26-22	Resumed	Barclays	Overweight
Oct-20-21	Upgrade	Citigroup	Neutral → Buy
Oct-15-21	Resumed	Cowen	Outperform
Aug-05-21	Resumed	Credit Suisse	Outperform
Jul-16-21	Initiated	The Benchmark Company	Buy
Mar-18-21	Upgrade	KeyBanc Capital Markets	Sector Weight → Overweight
Mar-03-21	Initiated	Barclays	Overweight
Jan-08-21	Upgrade	Credit Suisse	Neutral → Outperform
Dec-16-20	Downgrade	Citigroup	Buy → Neutral
Dec-02-20	Initiated	Goldman	Buy
Nov-10-20	Initiated	KeyBanc Capital Markets	Sector Weight
Sep-30-20	Initiated	Atlantic Equities	Overweight
Sep-14-20	Initiated	Morgan Stanley	Overweight
Aug-20-20	Resumed	JP Morgan	Overweight
Jul-15-20	Upgrade	Cleveland Research	Neutral → Buy
Jul-07-20	Reiterated	Needham	Buy
Apr-23-20	Reiterated	Needham	Buy
Jan-31-20	Reiterated	Needham	Buy
Jan-22-20	Initiated	Credit Suisse	Neutral
Jan-08-20	Initiated	Wells Fargo	Equal Weight
Jan-07-20	Initiated	Citigroup	Buy
Nov-15-19	Initiated	Stifel	Buy
Jul-25-19	Reiterated	Needham	Buy
Jul-16-19	Downgrade	Needham	Strong Buy → Buy
May-30-19	Initiated	Wolfe Research	Outperform
May-23-19	Reiterated	Needham	Strong Buy
Apr-22-19	Reiterated	Needham	Strong Buy
Apr-16-19	Reiterated	BofA/Merrill	Buy

Thermo Fisher Scientific Inc Stock (TMO) Financials Data

Period	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period End Date	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Revenue USD (M)	44,556.00	42,879.00	42,857.00	44,915.00	39,211.00
Research and development USD (M)	1,397.00	1,390.00	1,337.00	1,471.00	1,406.00
Operating expenses USD (M)	36,810.00	35,542.00	35,998.00	36,522.00	29,183.00
Operating income USD (M)	7,746.00	7,337.00	6,859.00	8,393.00	10,028.00
Income before tax USD (M)	7,308.00	7,037.00	6,298.00	7,835.00	8,841.00
Income tax expense USD (M)	547.00	657.00	284.00	703.00	1,109.00
Net income USD (M)	6,721.00	6,338.00	5,955.00	6,960.00	7,728.00
Basic EPS USD/shares	17.77	16.58	15.52	17.75	19.62
Diluted EPS USD/shares	17.74	16.53	15.45	17.63	19.46
Basic weighted shares shares (M)	377.00	382.00	386.00	392.00	394.00
Diluted weighted shares shares (M)	378.00	383.00	388.00	394.00	397.00
Selling, general and administrative USD (M)	8,732.00	8,595.00	8,445.00	8,993.00	8,007.00

Thermo Fisher Scientific Inc Stock (TMO) Insider Trading

Britt Lisa P.Oct 28 '26
Officer
Transaction
Proposed Sale
Cost
$706.45
#Shares
2,831
Value ($)
1,999,960
#Shares Total
0
Britt Lisa P.Oct 28 '26
Sr. VP and Chief HR Officer
Transaction
Sale
Cost
$706.45
#Shares
2,831
Value ($)
1,999,960
#Shares Total
11,560
Pettiti GianlucaAug 31 '26
President & COO
Transaction
Sale
Cost
$614.38
#Shares
4,133
Value ($)
2,539,233
#Shares Total
23,216
Pettiti GianlucaAug 31 '26
Officer
Transaction
Proposed Sale
Cost
$614.38
#Shares
4,133
Value ($)
2,539,233
#Shares Total
0
Pettiti GianlucaAug 31 '26
President & COO
Transaction
Option Exercise
Cost
$309.63
#Shares
3,733
Value ($)
1,155,849
#Shares Total
26,949
CASPER MARC NAug 24 '26
Chairman & CEO
Transaction
Sale
Cost
$627.05
#Shares
275
Value ($)
172,439
#Shares Total
123,925
CASPER MARC NAug 24 '26
Officer
Transaction
Proposed Sale
Cost
$627.05
#Shares
275
Value ($)
172,438
#Shares Total
0
CASPER MARC NAug 24 '26
Chairman & CEO
Transaction
Option Exercise
Cost
$309.63
#Shares
275
Value ($)
85,148
#Shares Total
124,200
CASPER MARC NAug 21 '26
Officer
Transaction
Proposed Sale
Cost
$626.91
#Shares
10,000
Value ($)
6,269,123
#Shares Total
0
CASPER MARC NAug 21 '26
Chairman & CEO
Transaction
Sale
Cost
$626.92
#Shares
10,000
Value ($)
6,269,153
#Shares Total
123,925

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
Britt Lisa P.	Officer	Oct 28 '26	Proposed Sale	$706.45	2,831	1,999,960	0
Britt Lisa P.	Sr. VP and Chief HR Officer	Oct 28 '26	Sale	$706.45	2,831	1,999,960	11,560
Pettiti Gianluca	President & COO	Aug 31 '26	Sale	$614.38	4,133	2,539,233	23,216
Pettiti Gianluca	Officer	Aug 31 '26	Proposed Sale	$614.38	4,133	2,539,233	0
Pettiti Gianluca	President & COO	Aug 31 '26	Option Exercise	$309.63	3,733	1,155,849	26,949
CASPER MARC N	Chairman & CEO	Aug 24 '26	Sale	$627.05	275	172,439	123,925
CASPER MARC N	Officer	Aug 24 '26	Proposed Sale	$627.05	275	172,438	0
CASPER MARC N	Chairman & CEO	Aug 24 '26	Option Exercise	$309.63	275	85,148	124,200
CASPER MARC N	Officer	Aug 21 '26	Proposed Sale	$626.91	10,000	6,269,123	0
CASPER MARC N	Chairman & CEO	Aug 21 '26	Sale	$626.92	10,000	6,269,153	123,925

Thermo Fisher Scientific Inc Stock (TMO) Latest News

Nov 02, 2026

If You Invested $1000 in Thermo Fisher Scientific a Decade Ago, This is How Much It'd Be Worth Now - Zacks Investment Research

Nov 02, 2026

Beat the Market Like Zacks: Marathon Petroleum, Amgen, Chevron in Focus - Zacks Investment Research

Nov 02, 2026

Oct 30, 2026

RMD Stock Up on Q1 Earnings and Revenue Beat, Gross Margin Climbs - Zacks Investment Research

Oct 30, 2026

Oct 28, 2026

Thailand Next Generation Sequencing (NGS) Market Size, Share, Trends, and Forecast - 2026 to 2036 | Precision Medicine Drives 12.7% CAGR and a $305.21 Million Opportunity - GlobeNewswire Inc.

Oct 28, 2026

Oct 27, 2026

15-year-old Designs Low-Cost Device to Monitor Airborne Bacteria in the Environment; Wins $25,000 Top Award at the 2026 Thermo Fisher Scientific Junior Innovators Challenge - GlobeNewswire Inc.

Oct 27, 2026

Top Research Reports for Alphabet, ExxonMobil & Toyota Motor - Zacks Investment Research

Oct 27, 2026

Oct 26, 2026

Thermo Fisher Scientific Inc. stock rises Monday, outperforms market - MarketWatch

Oct 26, 2026

Oct 25, 2026